AAAAAA

   
Results: 1-16 |
Results: 16
Farnesyl : protein transferase inhibitors as potential agents for the management of human prostate cancer
Authors: Sepp-Lorenzino, L Tjaden, G Moasser, MM Timaul, N Ma, Z Kohl, NE Gibbs, JB Oliff, A Rosen, N Scher, HI
Citation: L. Sepp-lorenzino et al., Farnesyl : protein transferase inhibitors as potential agents for the management of human prostate cancer, PROSTATE C, 4(1), 2001, pp. 33-43
2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase
Authors: Trotter, BW Quigley, AG Lumma, WC Sisko, JT Walsh, ES Hamann, CS Robinson, RG Bhimnathwala, H Kolodin, DG Zheng, W Buser, CA Huber, HE Lobell, RB Kohl, NE Williams, TM Graham, SL Dinsmore, CJ
Citation: Bw. Trotter et al., 2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase, BIOORG MED, 11(7), 2001, pp. 865-869
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase
Authors: Dinsmore, CJ Bergman, JM Wei, DD Zartman, CB Davide, JP Greenberg, IB Liu, DM O'Neill, TJ Gibbs, JB Koblan, KS Kohl, NE Lobell, RB Chen, IW McLoughlin, DA Olah, TV Graham, SL Hartman, GD Williams, TM
Citation: Cj. Dinsmore et al., Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase, BIOORG MED, 11(4), 2001, pp. 537-540
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors offarnesyl-protein transferase
Authors: Beshore, DC Bell, IM Dinsmore, CJ Homnick, CF Culberson, JC Robinson, RG Fernandes, C Walsh, ES Abrams, MT Bhimnathwala, HG Davide, JP Ellis-Hutchings, MS Huber, HA Koblan, KS Buser, CA Kohl, NE Lobell, RB Chen, IW McLoughlin, DA Olah, TV Graham, SL Hartman, GD Williams, TM
Citation: Dc. Beshore et al., Evaluation of amino acid-based linkers in potent macrocyclic inhibitors offarnesyl-protein transferase, BIOORG MED, 11(14), 2001, pp. 1817-1821
Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I
Authors: Bergman, JM Abrams, MT Davide, JP Greenberg, IB Robinson, RG Buser, CA Huber, HE Koblan, KS Kohl, NE Lobell, RB Graham, SL Hartman, GD Williams, TM Dinsmore, CJ
Citation: Jm. Bergman et al., Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I, BIOORG MED, 11(11), 2001, pp. 1411-1415
Diaryl ether inhibitors of farnesyl-protein transferase
Authors: MacTough, SC DeSolms, SJ Shaw, AW Abrams, MT Ciccarone, TR Davide, JP Hamilton, KA Hutchinson, JH Koblan, KS Kohl, NE Lobell, RB Robinson, RG Graham, SL
Citation: Sc. Mactough et al., Diaryl ether inhibitors of farnesyl-protein transferase, BIOORG MED, 11(10), 2001, pp. 1257-1260
Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency
Authors: Bell, IM Gallicchio, SN Abrams, M Beshore, DC Buser, CA Culberson, JC Davide, J Ellis-Hutchings, M Fernandes, C Gibbs, JB Graham, SL Hartman, GD Heimbrook, DC Homnick, CF Huff, JR Kassahun, K Koblan, KS Kohl, NE Lobell, RB Lynch, JJ Miller, PA Omer, CA Rodrigues, AD Walsh, ES Williams, TM
Citation: Im. Bell et al., Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency, J MED CHEM, 44(18), 2001, pp. 2933-2949
Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice
Authors: Gibbs, JB Graham, SL Hartman, GD Koblan, KS Kohl, NE Omer, C Pellicier, A Windle, J Oliff, A
Citation: Jb. Gibbs et al., Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice, CANC DRUG, 8, 2001, pp. 65-70
A peptidomimetic inhibitor of ras functionality markedly suppresses growthof human prostate tumor xenografts in mice. Prospects for long-term clinical utility
Authors: Sirotnak, FM Sepp-Lorenzino, L Kohl, NE Rosen, N Scher, HI
Citation: Fm. Sirotnak et al., A peptidomimetic inhibitor of ras functionality markedly suppresses growthof human prostate tumor xenografts in mice. Prospects for long-term clinical utility, CANC CHEMOT, 46(1), 2000, pp. 79-83
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl : protein transferase inhibitor
Authors: Omer, CA Chen, ZX Diehl, RE Conner, MW Chen, HY Trumbauer, ME Gopal-Truter, S Seeburger, G Bhimnathwala, H Abrams, MT Davide, JP Ellis, MS Gibbs, JB Greenberg, I Hamilton, K Koblan, KS Kral, AM Liu, DM Lobell, RB Miller, PJ Mosser, SD O'Neill, TJ Rands, E Schaber, MD Senderak, ET Oliff, A Kohl, NE
Citation: Ca. Omer et al., Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl : protein transferase inhibitor, CANCER RES, 60(10), 2000, pp. 2680-2688
Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
Authors: Norgaard, P Law, B Joseph, H Page, DL Shyr, Y Mays, D Pietenpol, JA Kohl, NE Oliff, A Coffey, RJ Poulsen, HS Moses, HL
Citation: P. Norgaard et al., Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis, CLIN CANC R, 5(1), 1999, pp. 35-42
Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase
Authors: Dinsmore, CJ Williams, TM O'Neill, TJ Liu, DM Rands, E Culberson, JC Lobell, RB Koblan, KS Kohl, NE Gibbs, JB Oliff, AI Graham, SL Hartman, GD
Citation: Cj. Dinsmore et al., Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase, BIOORG MED, 9(23), 1999, pp. 3301-3306
Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase
Authors: Ciccarone, TM MacTough, SC Williams, TM Dinsmore, CJ O'Neill, TJ Shah, D Culberson, JC Koblan, KS Kohl, NE Gibbs, JB Oliff, AI Graham, SL Hartman, GD
Citation: Tm. Ciccarone et al., Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase, BIOORG MED, 9(14), 1999, pp. 1991-1996
N-arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity
Authors: Williams, TM Bergman, JM Brashear, K Breslin, MJ Dinsmore, CJ Hutchinson, JH MacTough, SC Stump, CA Wei, DD Zartman, CB Bogusky, MJ Culberson, JC Buser-Doepner, C Davide, J Greenberg, IB Hamilton, KA Koblan, KS Kohl, NE Liu, DM Lobell, RB Mosser, SD O'Neill, TJ Rands, E Schaber, MD Wilson, F Senderak, E Motzel, SL Gibbs, JB Graham, SL Heimbrook, DC Hartman, GD Oliff, AI Huff, JR
Citation: Tm. Williams et al., N-arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity, J MED CHEM, 42(19), 1999, pp. 3779-3784
Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase
Authors: Anthony, NJ Gomez, RP Schaber, MD Mosser, SD Hamilton, KA O'Neil, TJ Koblan, KS Graham, SL Hartman, GD Shah, D Rands, E Kohl, NE Gibbs, JB Oliff, AI
Citation: Nj. Anthony et al., Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase, J MED CHEM, 42(17), 1999, pp. 3356-3368
In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells
Authors: Mahgoub, N Taylor, BR Gratiot, M Kohl, NE Gibbs, JB Jacks, T Shannon, KM
Citation: N. Mahgoub et al., In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells, BLOOD, 94(7), 1999, pp. 2469-2476
Risultati: 1-16 |